Unrestrained activation of the JAK/STAT pathways contributes to a number of autoimmune diseases and proliferative disorders, making JAKs an attractive target for pharmacologic manipulation in the treatment of such conditions (8, 9). Here, SOAT1 is linked to autoimmune disease.